Intellikine, a Leading Developer of Small Molecule Drugs Targeting the PI3K/mTOR Pathway, Names Dr. Gregory Berk CMO

Intellikine, a Leading Developer of Small Molecule Drugs Targeting the PI3K/mTOR Pathway, Names Dr. Gregory Berk Chief Medical Officer

Appointment Strengthens Intellikine's Development Expertise and Supports Expanding, Clinical-Stage Product Pipeline

LA JOLLA, Calif.--(BUSINESS WIRE)--Intellikine, Inc. announced today the appointment of Gregory I. Berk, M.D. as Chief Medical Officer. Prior to joining Intellikine, Dr. Berk served as Senior Vice President of Global Clinical Development at Celgene Corporation, where he was a key member of the Celgene-Abraxis Integration team during Celgene's acquisition of Abraxis BioScience. Prior to Celgene, Dr. Berk was Senior Vice President of Global Clinical Development at Abraxis BioScience, where he was responsible for the company's overall clinical strategy, including efforts to expand the indications for Abraxane® in lung cancer, pancreatic cancer and malignant melanoma.

"Since its inception four years ago, Intellikine has rapidly advanced multiple, clinical-stage programs that are now generating exciting data as well as significant interest from clinical investigators, collaborators, foundations and corporate partners," said Troy Wilson, Ph.D., J.D., President and CEO of Intellikine. "We are excited to work with Greg to continue to build Intellikine and advance our drug candidates to the patients who so urgently need them."

Intellikine has assembled one of the leading pipelines of clinical-stage, small molecule drugs against the PI3K/mTOR pathway for the treatment of patients with cancer and other serious diseases. The company's most advanced program, INK128, a TORC1/2 inhibitor, has generated encouraging data in multiple Phase I studies and will enter Phase II studies in early 2012. In addition, both INK1117, a selective PI3Kalpha inhibitor, and IPI-145 (formerly INK1197), a potent PI3Kdelta/gamma inhibitor partnered with Infinity Pharmaceuticals, are poised to enter human clinical testing later this year. Beyond the three lead programs, Intellikine continues to generate an exciting pipeline of additional investigational drug candidates.

"I was attracted to Intellikine by the high quality of the people, the drug candidates and the science," said Dr. Berk. "The company is one of the leaders at targeting specific patient populations with selective inhibitors with the opportunity to impact patients with solid tumors and hematologic malignancies. I look forward to working with the Intellikine team, the clinical investigators, our investors and partners, as we capitalize on recent accomplishments in our pursuit to build an industry-leading oncology company."

About Intellikine

Intellikine is a private, clinical-stage company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway for the treatment of cancer and other serious diseases. Intellikine's most advanced drug candidate, INK128, a novel TORC1/2 inhibitor, is being investigated in multiple Phase 1 clinical trials, including in patients with advanced solid tumors, patients with Multiple Myeloma and Waldenstrom's macroglobulinemia and in combination with paclitaxel in patients with advanced solid tumors. Intellikine is also developing INK1117, an inhibitor of PI3Kalpha, for which an IND has been approved and for which the Company plans to advance into Phase 1 in the second half of 2011. Intellikine owns all the rights to both INK128 and INK1117. In July 2010, Intellikine entered into a $489 million collaborative partnership with Infinity Pharmaceuticals to develop oral therapies targeting PIK3Kdelta and PI3Kgamma for indications including immune-mediated inflammatory diseases and cancer. Among these inhibitors is IPI-145 (formerly INK1197), an orally available inhibitor of both PI3Kdelta and PI3Kgamma. Infinity and Intellikine anticipate advancing IPI-145 into Phase 1 study in the second half of 2011. Intellikine has raised $41 million from outstanding investors and has attracted significant support from leading foundations such as the Multiple Myeloma Research Foundation and the Polycystic Kidney Disease Foundation.

For more information, please visit the company's website at www.intellikine.com.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.